Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females
Asvini K Subasinghe, John D Wark, Samuel Phillips, Alyssa Cornall, Julia ML Brotherton, Suzanne M Garland
Sexual Health | CSIRO PUBLISHING | Published : 2020
Background The prevalence of genital tract vaccine-type human papillomavirus (HPV) is on the decline due to high vaccine uptake through the national HPV immunisation program in Australia. The aim of this study was to investigate HPV vaccine coverage and factors associated with HPV in a vaccine-eligible sample of young Australian females. METHODS: Females aged 16-25 years were recruited into the Young Female Health Initiative study, a young women's health study, via Facebook advertising from 2012 to 2017. Sexually active participants were asked to provide a self-collected vaginal swab for the detection of HPV DNA; positive samples were genotyped. Self-reported HPV vaccination status was confi..View full abstract
Awarded by National Health and Medical Research Council
Awarded by Merck Sharp & Dohme investigator-initiated study grant
The authors thank the research nurses, students and other staff who helped collect the data for the Young Female Health Initiative study, as well as the participants, without whom this study would not have been possible. This work was funded by a National Health and Medical Research Council program grant (568971) and a Merck Sharp & Dohme investigator-initiated study grant (IISP 40509) 'Monitoring the effectiveness of the Australian cervical cancer vaccine program: translation to reduction in vaccine related HPV infection'.